NeuroCog Trials, Inc. today announced the publication of research conducted at Duke University on The Schizophrenia Cognition Rating Scale (SCoRS), an interview-based reliable and valid measure of cognition in schizophrenia. This newest addition to NeuroCog Trials’ growing library of cognitive assessments is designed to enable reliable and valid measurement of patients’ cognitive functioning in clinical trials of new medicines for schizophrenia.
Richard Keefe, Ph.D., NeuroCog Trials Founder and CEO, and lead author of the publication in this month’s American Journal of Psychiatry, said, “I am pleased to see our work on the SCoRS published so that it can be used as an interview-based assessment tool to enhance both clinical research and practice.”
The primary method of gathering information for clinicians, talking with patients and their families, has had no systematic interview schedule that could produce a reliable and valid assessment of patients’ cognitive functioning. In addition, clinical trials with some patient groups may have difficulty implementing traditional paper and pencil tests of cognitive functioning. The Schizophrenia Cognition Rating Scale (SCoRS) has the potential to meet these needs.
Further, Dr. Keefe added, “We are encouraged by the recommendations of an FDA NIMH MATRICS panel that suggested both functional capacity and interview-based assessment as co-primary measures for cognition in clinical trials. With today’s publication, the field now has both types of assessment tools for this important area of drug development.”